Chaired by Howard P. Milstein and Abby S. Milstein
The Howard and Abby Milstein Foundation is taking on some of the most challenging issues facing the world today. The Foundation has been active for fifteen years — for the last five years under the current name and, in the previous ten years, as the Howard P. Milstein Foundation.
Howard and Abby’s involvement, leadership and giving align with the essence of “Venture Philanthropy”, which brings the principles of venture capitalism to philanthropy. These include active engagement in organization and operations; encouraging an entrepreneurial approach to innovation and change; and finding and investing in leaders in the field. The Howard and Abby Milstein Foundation’s strategic gifts, institutional leadership and hands-on involvement stimulate innovation, create efficiencies and produce results. Howard and Abby participate financially, intellectually and emotionally in the organizations they support.
Seven core areas have emerged from their vision:
- Medical Research, Biotechnology & Science
- Higher Education & Youth
- Religious and Communal Organizations
- Arts & Culture
- Law Enforcement & Homeland Security
- Civic Engagement
A unique collaboration of patients, families, advocates, physicians and scientists, American Skin Association has evolved over the past two decades as a leading force in efforts to defeat melanoma, skin cancer and disease.
Established to serve the now more than 100 million Americans — one third of the U.S. population — afflicted with skin disorders, the organization’s mission remains to…
- Advance research
- Champion skin health — particularly among children
- Drive public awareness about skin disease
As Chairman of the Board of the American Skin Association, Howard Milstein has brought stability to the organization, increased its assets and sharpened its focus on cancer and melanoma. As such, he is in the vanguard of those who are working to combat the deadly effects of climate change on the skin.
Chaired by Howard P. Milstein
The Jones Foundation for Reproductive Medicine is a nonprofit organization dedicated to advancing scientific and medical research in the field of reproductive medicine. The Foundation strives to provide resources to the scientific community so that there may be intellectual, creative and well prepared scientific leaders in the global environment of the 21st century by:
- Fostering the development of innovative, high-quality research by new and established investigators in the field of reproductive medicine.
- Educating the general public, including physicians, administrators and legislators, about the issues of public policy topics that will assist the general public and others in making informed decisions regarding fertility treatment and reproductive medical issues.
- Serving as catalyst to scientific investigators by reviewing and selecting for an annual Award, one or more significant research projects that advanced the field of reproductive medicine.
New York Blood Center (NYBC), established in 1964, is one of the largest community-based, non-profit blood collection and distribution organizations in the United States. Through the integrated efforts of our Blood Services operation, NYBC annually provides nearly one million blood components to nearly 200 hospitals throughout New York City, New Jersey, Hudson Valley, Long Island and parts of Connecticut and Pennsylvania. The population served by NYBC exceeds 22 million people.
New York Blood Center’s Milstein National Cord Blood Center (supported by the Howard and Abby Milstein Foundation) and its National Cord Blood Program (NCBP) is the world’s oldest and remains the largest single public cord blood bank. We collect, process, test and store cord blood that mothers donate to us for use by patient in need for a hematopoietic stem cell transplant. The Center’s Program makes cord blood available under an Investigational New Drug (IND) exemption from the U.S. Food and Drug Administration (IND) exemption from the U.S. Food and Drug Administration (FDA) for children and adults who face a life-threatening illness and need “stem cell” transplants from unrelated donors. NYBC’s NCBP was also the first public cord blood bank in the world to receive NetCord-FACT accreditation (June 2003).
Milstein Medical Research Program at The Rockefeller University
In 2007, the Milstein family launched the Milstein Medical Research Program at The Rockefeller University, led by Dr. James Krueger. Dr. Krueger’s early work led to a revolution in the treatment of psoriasis. He found that T-cells, rather than an aberration of the immune system, were the triggering mechanism for psoriasis. That discovery led to a whole new world of drugs for treating the widespread skin disease. This has been a special boon for sufferers of psoriatic arthritis, which is totally crippling.
Dr. Krueger is now applying the same out-of-the-box thinking to the Milstein Medical Research Program, where the initial focus is melanoma. With depletion of the ozone layer, melanoma is becoming an ever greater threat. The greatest hope for a cure is to understand the initial step in the metastatic process and block it there. Dr. Krueger and his team are using advanced genetic methods and imaging techniques to learn how “melanocyte” skin cells become malignant. Information gained from these experiments will lead to much more accurate diagnostic techniques and more effective treatments.
Abby and Howard Milstein Chemical Core Facility and Program in Chemical Biology at Weill Cornell Medical College
In 2003, the Howard P. Milstein Computational Biomedicine Programmatic Core was established at the Weill Cornell Medical College, where Howard Milstein has served as a Trustee since 1986.
Tuberculosis, Malaria and HIV/AIDS are killing millions of people each year. Beyond the human tragedy of these losses is the destabilizing economic and political impact of these deaths in Africa and other parts of the developing world. Disease travels across continents, making this a vital concern — not just for the international community, but for Americans, as well.
In response to these needs, the Abby and Howard Milstein Chemical Core Facility and the Abby and Howard Milstein Program in Chemical Biology at Weill Cornell Medical College are funding breakthrough research. Under the aegis of Dr. Carl Nathan, a dual antigen cure for antibiotic-resistant infections is underway. The double antigen cure could intercept the normal mutation process that occurs every 500 generations and change that to every trillion generations. In short, the mutations that lead to antibiotic resistance would be slowed to a point where the impact on pharmaceutical treatments would be almost non-existent. This would greatly increase the effective lifespan of new antibiotics developed by Weill Cornell and other research centers. One of the priorities that the Milsteins have built into the research program is the development of new drugs that would be delivered at the lowest possible cost to the needy populations in Africa.